198 related articles for article (PubMed ID: 32754897)
1. Targeting of Perforin Inhibitor into the Brain Parenchyma Via a Prodrug Approach Can Decrease Oxidative Stress and Neuroinflammation and Improve Cell Survival.
Tampio J; Huttunen J; Montaser A; Huttunen KM
Mol Neurobiol; 2020 Nov; 57(11):4563-4577. PubMed ID: 32754897
[TBL] [Abstract][Full Text] [Related]
2. Astrocyte-Targeted Transporter-Utilizing Derivatives of Ferulic Acid Can Have Multifunctional Effects Ameliorating Inflammation and Oxidative Stress in the Brain.
Montaser A; Huttunen J; Ibrahim SA; Huttunen KM
Oxid Med Cell Longev; 2019; 2019():3528148. PubMed ID: 31814871
[TBL] [Abstract][Full Text] [Related]
3. Hemocompatible L-Type amino acid transporter 1 (LAT1)-Utilizing prodrugs of perforin inhibitors can accumulate into the pancreas and alleviate inflammation-induced apoptosis.
Tampio J; Markowicz-Piasecka M; Huttunen KM
Chem Biol Interact; 2021 Aug; 345():109560. PubMed ID: 34153225
[TBL] [Abstract][Full Text] [Related]
4. L-Type amino acid transporter 1 (lat1)-mediated targeted delivery of perforin inhibitors.
Huttunen KM; Huttunen J; Aufderhaar I; Gynther M; Denny WA; Spicer JA
Int J Pharm; 2016 Feb; 498(1-2):205-16. PubMed ID: 26705152
[TBL] [Abstract][Full Text] [Related]
5. L-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and Microglia.
Huttunen J; Peltokangas S; Gynther M; Natunen T; Hiltunen M; Auriola S; Ruponen M; Vellonen KS; Huttunen KM
Sci Rep; 2019 Sep; 9(1):12860. PubMed ID: 31492955
[TBL] [Abstract][Full Text] [Related]
6. Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs.
Gynther M; Pickering DS; Spicer JA; Denny WA; Huttunen KM
Mol Pharm; 2016 Jul; 13(7):2484-91. PubMed ID: 27266990
[TBL] [Abstract][Full Text] [Related]
7. L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery.
Puris E; Gynther M; Huttunen J; Auriola S; Huttunen KM
Eur J Pharm Sci; 2019 Mar; 129():99-109. PubMed ID: 30625368
[TBL] [Abstract][Full Text] [Related]
8. Improved l-Type amino acid transporter 1 (LAT1)-mediated delivery of anti-inflammatory drugs into astrocytes and microglia with reduced prostaglandin production.
Tampio J; Löffler S; Guillon M; Hugele A; Huttunen J; Huttunen KM
Int J Pharm; 2021 May; 601():120565. PubMed ID: 33812973
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's Disease Phenotype or Inflammatory Insult Does Not Alter Function of L-Type Amino Acid Transporter 1 in Mouse Blood-Brain Barrier and Primary Astrocytes.
Gynther M; Puris E; Peltokangas S; Auriola S; Kanninen KM; Koistinaho J; Huttunen KM; Ruponen M; Vellonen KS
Pharm Res; 2018 Nov; 36(1):17. PubMed ID: 30488131
[TBL] [Abstract][Full Text] [Related]
10. L-Type Amino Acid Transporter 1 Enables the Efficient Brain Delivery of Small-Sized Prodrug across the Blood-Brain Barrier and into Human and Mouse Brain Parenchymal Cells.
Montaser AB; Järvinen J; Löffler S; Huttunen J; Auriola S; Lehtonen M; Jalkanen A; Huttunen KM
ACS Chem Neurosci; 2020 Dec; 11(24):4301-4315. PubMed ID: 33228353
[TBL] [Abstract][Full Text] [Related]
11. L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugs.
Puris E; Gynther M; Huttunen J; Petsalo A; Huttunen KM
J Control Release; 2017 Sep; 261():93-104. PubMed ID: 28662899
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic Study on the Use of the l-Type Amino Acid Transporter 1 for Brain Intracellular Delivery of Ketoprofen via Prodrug: A Novel Approach Supporting the Development of Prodrugs for Intracellular Targets.
Puris E; Gynther M; de Lange ECM; Auriola S; Hammarlund-Udenaes M; Huttunen KM; Loryan I
Mol Pharm; 2019 Jul; 16(7):3261-3274. PubMed ID: 31180686
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine.
Peura L; Malmioja K; Huttunen K; Leppänen J; Hämäläinen M; Forsberg MM; Gynther M; Rautio J; Laine K
Pharm Res; 2013 Oct; 30(10):2523-37. PubMed ID: 24137801
[TBL] [Abstract][Full Text] [Related]
14. Enhanced drug delivery by a prodrug approach effectively relieves neuroinflammation in mice.
Montaser AB; Kuiri J; Natunen T; Hruška P; Potěšil D; Auriola S; Hiltunen M; Terasaki T; Lehtonen M; Jalkanen A; Huttunen KM
Life Sci; 2022 Dec; 310():121088. PubMed ID: 36257461
[TBL] [Abstract][Full Text] [Related]
15. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery.
Peura L; Malmioja K; Laine K; Leppänen J; Gynther M; Isotalo A; Rautio J
Mol Pharm; 2011 Oct; 8(5):1857-66. PubMed ID: 21770378
[TBL] [Abstract][Full Text] [Related]
16. Secondary carbamate linker can facilitate the sustained release of dopamine from brain-targeted prodrug.
Thiele NA; Kärkkäinen J; Sloan KB; Rautio J; Huttunen KM
Bioorg Med Chem Lett; 2018 Sep; 28(17):2856-2860. PubMed ID: 30055889
[TBL] [Abstract][Full Text] [Related]
17. Flavanone glycosides inhibit β-site amyloid precursor protein cleaving enzyme 1 and cholinesterase and reduce Aβ aggregation in the amyloidogenic pathway.
Ali MY; Jannat S; Edraki N; Das S; Chang WK; Kim HC; Park SK; Chang MS
Chem Biol Interact; 2019 Aug; 309():108707. PubMed ID: 31194956
[TBL] [Abstract][Full Text] [Related]
18. L-type Amino Acid Transporter 1 Utilizing Ferulic Acid Derivatives Show Increased Drug Delivery in the Mouse Pancreas Along with Decreased Lipid Peroxidation and Prostaglandin Production.
Tampio J; Markowicz-Piasecka M; Montaser A; Rysä J; Kauppinen A; Huttunen KM
Mol Pharm; 2022 Nov; 19(11):3806-3819. PubMed ID: 36027044
[TBL] [Abstract][Full Text] [Related]
19. Management of oxidative stress and other pathologies in Alzheimer's disease.
Simunkova M; Alwasel SH; Alhazza IM; Jomova K; Kollar V; Rusko M; Valko M
Arch Toxicol; 2019 Sep; 93(9):2491-2513. PubMed ID: 31440798
[TBL] [Abstract][Full Text] [Related]
20. L-F001, a novel multifunctional ROCK inhibitor, suppresses neuroinflammation in vitro and in vivo: Involvement of NF-κB inhibition and Nrf2 pathway activation.
Chen J; Yin W; Tu Y; Wang S; Yang X; Chen Q; Zhang X; Han Y; Pi R
Eur J Pharmacol; 2017 Jul; 806():1-9. PubMed ID: 28320516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
